患有前列腺癌的男性服用第二代雄激素受体对抗剂的跌倒和骨折:回顾性图表审查
1Department of Pharmacy Practice, University of Connecticut School of Pharmacy, Storrs, CT, USA.
概括
在接受恩扎胺治疗的前列腺癌患者中,跌倒和骨折的发生率比之前报告的更高. 骨转移和神经病变等并发症可能会增加这种雌激素受体对手的跌倒和骨折风险.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 第二代雄激素受体抗剂 (恩扎胺,阿帕胺,达罗胺) 是前列腺癌的标准治疗方法.
- 虽然一般耐受性很好,但临床试验报告了跌倒 (4.2-15.6%) 和骨折 (4.2-11.7%).
- 营销后的研究表明,发病率低于最初的临床试验.
研究的目的:
- 确定 UConn Health 在接受第二代雄激素受体对抗剂治疗的前列腺癌患者中跌倒和骨折的患病率.
- 在这个患者群体中确定与跌倒和骨折相关的潜在风险因素.
主要方法:
- 在2022年3月至2023年3月期间,对接受达罗胺,恩扎胺或阿帕胺治疗的前列腺癌患者的回顾性图表审查.
- 收集的数据包括人口统计,跌倒/骨折史,转移,跌倒风险,骨质疏松症和并发症.
- 描述性统计数据被用于数据评估.
主要成果:
- 26名患者接受了恩扎胺;96.1%的人患有骨转移,15.4%患有骨质疏松症,15.4%患有骨质疏松症,34.6%在基线时患有神经病变.
- 跌倒的发生率为19.2%,骨折的发生率为26.9%.
- 患有跌倒的患者经常患有关节痛,神经病变,步行问题,高血压,并且有跌倒的风险. 骨折与骨转移和denosumab使用有关.
结论:
- 观察到的跌倒和骨折的患病率超过了临床试验和营销后研究报告的率.
- 较高的发病率可能与小样本大小或患者的相关疾病 (如骨质疏松症,骨转移或神经病变) 有关.
- 跌倒/骨折的风险和促成因素应在恩扎胺治疗讨论和监测计划时考虑.
相关概念视频
01:20Disorders of the Male Reproductive System
342
Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
342
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
394
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
394
01:22Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
549
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
549
01:29Bone Disorders
3.4K
Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
3.4K
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
154
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
154
01:28Menopause
143
Menopause, a natural biological process marking the end of a woman's fertility, typically occurs between the fifth and sixth decade of life. This phase is characterized by the exhaustion of the ovarian follicle pool, leading to less responsive ovaries despite the high levels of Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH). The consequential decrease in estrogen production results in symptoms like hot flashes, heavy sweating, headaches, hair loss, muscle pains, vaginal...
143